Vivace Therapeutics Highlights VT3989 Mesothelioma Data and Path Toward Phase 3 Trial

According to a recent LinkedIn post from Vivace Therapeutics Inc, an episode of MesoTV sponsored by the Mesothelioma Applied Research Foundation features Dr. Timothy Yap of UT MD Anderson Cancer Center discussing the company’s VT3989-001 trial. The therapy, VT3989, is described as a YAP/TEAD inhibitor designed to disrupt intracellular signaling that supports mesothelioma tumor growth and survival.

The post highlights what it characterizes as compelling efficacy in both pleural and non-pleural refractory mesothelioma, along with a favorable safety profile with few treatment-related adverse events above Grade 3. It further suggests that the observed results support advancing VT3989 into a registrational third‑line Phase 3 study in mesothelioma, indicating a potential path toward pivotal data.

For investors, the suggestion of registrational intent implies that VT3989 may be moving closer to a value‑defining late‑stage development milestone, albeit still subject to Phase 3 design, execution, and regulatory review risks. Positive safety and efficacy impressions, if replicated in larger controlled trials, could enhance Vivace Therapeutics’ standing in oncology drug development and strengthen its position for future financing, partnerships, or an eventual exit.

Within the competitive mesothelioma landscape, a targeted YAP/TEAD inhibitor with supportive early‑stage data could address an area of high unmet medical need where approved options are limited. However, commercial potential will ultimately depend on Phase 3 outcomes, comparative performance versus existing therapies, and payer adoption, all of which remain uncertain at this stage despite the encouraging tone of the LinkedIn content.